Global Cell-based Assay Market 2015-2019
About cell-based assay
Cell-based assays are used to measure biochemical or cellular functions such as cell motility, morphology, cell proliferation, toxicity, and stem cell differentiation. The components of cell-based assays include instruments and consumables. These components are used for screening and analysis of the cell functionality. The ease-of-use and accuracy of measurements make them important component in various research and commercial applications such as drug discovery and toxicology.
Technavio's analysts forecast the global cell-based assay market to grow at a CAGR of 11.3% during 2014-2019.
Covered in this report
The report includes the present scenario and the growth prospects of the global cell-based assay market for the period 2015-2019. Based on application, the market can be segmented into drug discovery and toxicology.Technavio's report, Global Cell-based Assay Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Technavio Announces the Publication of its Research Report – Global Cell-based Assay Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Cell-based Assay Market: EMD Millipore, Perkin Elmer, Sigma-Aldrich and Life Technologies (a subsidiary of Thermo Fisher Scientific)
Other Prominent Vendors in the market are: Agilent Technologies, Attana, BioTek Instruments, BioVision, BMG LABTECH, Cayman Chemical, Cisbio Bioassays, Corning, DiscoveRx, F. Hoffmann-La Roche, ProQinase, XENOMETRIX, Molecular Devices, Pall Corporation and Promega Corporation
Commenting on the report, an analyst from Technavio’s team said: “For analyzing a large amount of drug samples, automation is required during cell-based assays. This process involves analyzing around tens of thousands of samples per day. Robotic automation can be applied in drug screening with some modifications of cell-based assay system such as microplate lid handling and the use of automated incubators, laminar flow hoods, and biosafety cabinets. Many research laboratories and pharmaceutical companies are taking an increased interest in using automated cell-based assay techniques in drug discovery processes, which is expected to propel market growth during the forecast period.”
According to the report, label-free cell-based assays analyze the target molecule without modifying it. As a result, these assays can screen complex targets. The assays are flexible for using various types of cells such as primary, mammalian, suspension, and adherent cells, propelling their adoption in the drug discovery segment. Label-free cell-based assays include GPCR, receptor panning, receptor tyrosine kinases, orphan receptor screening, and ion channels. Many consumers use these assays complementarily to the traditional assay technology.
Further, the report states that the lack technical expertise of medical professionals results in operational and technological issues, which hinders the adoption of these complex assays.
EMD Millipore, Perkin Elmer, Sigma-Aldrich, Life Technologies (a subsidiary of Thermo Fisher Scientific), Agilent Technologies, Attana, BioTek Instruments, BioVision, BMG LABTECH, Cayman Chemical, Cisbio Bioassays, Corning, DiscoveRx, F. Hoffmann-La Roche, ProQinase, XENOMETRIX, Molecular Devices, Pall Corporation, Promega Corporation